Tyra Biosciences price target raised to $53 from $37 at Wedbush

Core Viewpoint - Wedbush analyst Robert Driscoll has raised the price target for Tyra Biosciences (TYRA) to $53 from $37 while maintaining an Outperform rating on the shares, indicating a positive outlook for the company based on recent developments in the industry [1]. Group 1: Company Analysis - The price target for Tyra Biosciences (TYRA) has been increased to $53 from $37, reflecting a bullish sentiment from Wedbush [1]. - The firm maintains an Outperform rating on Tyra Biosciences, suggesting confidence in the company's future performance [1]. Group 2: Industry Insights - BridgeBio (BBIO) announced positive topline Phase 3 data for infigratinib in achondroplasia, which validates FGFR3 inhibition as an effective mechanism for increasing height velocity in patients with skeletal dysplasia [1]. - The positive data from BridgeBio is seen as encouraging for dabogratinib, a more selective FGFR3 inhibitor, which is expected to show significant increases in absolute annual height velocity (AHV) and potentially lead to clinically important changes in proportionality [1].